Data partners can choose to initiate their own questions and participate (or not) in those posed by other data partners. These are just a few examples; as HONEUR evolves, answers to other questions will follow.
“What is the overall survival of patients with relapsed and/or refractory multiple myeloma who received at least three prior lines of therapy including proteasome inhibitors, immunomodulatory IMiD drugs, and CD38 monoclonal antibody treatment?”
“What is the time to next treatment, disease progression and long-term overall survival over a 5-year period in the real world vs. predicted overall survival data from clinical trials?”
“What are the treatment sequences in different countries and associated outcomes, e.g. overall survival?”
ITEM CODE: CP-180162 | DATE OF PREPARATION: SEPTEMBER 2020